We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current LILY34 market cap is 157.11B. The company's latest EPS is USD 5.5202 and P/E is 144.14.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 9.5B | 9.35B | 8.77B | 11.3B | 11.44B |
| Operating Income | -3.24B | 2.4B | 2.51B | 4.15B | 1.61B |
| Net Income | -57.4M | 2.19B | 2.24B | 2.97B | 970.3M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 22.32B | 24.56B | 28.32B | 28.54B | 34.12B |
| Operating Income | 5.47B | 6.06B | 6.66B | 7.37B | 6.46B |
| Net Income | 8.32B | 6.19B | 5.58B | 6.24B | 5.24B |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 57.92B | 64.01B | 63.94B | 71.87B | 75.61B |
| Total Liabilities | 46.61B | 53.14B | 51.05B | 58.24B | 61.29B |
| Total Equity | 11.31B | 10.86B | 12.9B | 13.64B | 14.32B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 39.29B | 46.63B | 48.81B | 49.49B | 64.01B |
| Total Liabilities | 36.59B | 40.81B | 39.65B | 38.71B | 53.14B |
| Total Equity | 2.7B | 5.83B | 9.15B | 10.78B | 10.86B |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 4.55B | 4.24B | 1.17B | 2.63B | 6.34B |
| Investing | -4.23B | -7.15B | -1.18B | -3.38B | -7.38B |
| Financing | -49.1M | 3.5B | -311.3M | 1.24B | 1.46B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 4.84B | 6.5B | 7.26B | 7.08B | 4.24B |
| Investing | -8.08B | -2.26B | -2.76B | -3.26B | -7.15B |
| Financing | -2.32B | -3.14B | -4.13B | -5.41B | 3.5B |
| Market Cap | 157.11B |
| Price to Earnings Ratio | 144.14 |
| Price to Sales Ratio | 22.13 |
| Price to Cash Ratio | 267.98 |
| Price to Book Ratio | 69.53 |
| Dividend Yield | 0.51% |
| Shares Outstanding | 949.31M |
| Average Volume (1 week) | 17.18k |
| Average Volume (1 Month) | 21.77k |
| 52 Week Change | 79.11% |
| 52 Week High | 181.98 |
| 52 Week Low | 91.08 |
| Spread (Intraday) | 2.85 (1.72%) |
| Company Name | Lilly Drn |
| Address |
334 north senate avenue indianapolis, indiana 46204 |
| Website | https://www.lilly.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
